22 reports of this reaction
4.9% of all MANGANESE SULFATE reports
#6 most reported adverse reaction
PULMONARY EMBOLISM is the #6 most commonly reported adverse reaction for MANGANESE SULFATE, manufactured by BM Private Limited. There are 22 FDA adverse event reports linking MANGANESE SULFATE to PULMONARY EMBOLISM. This represents approximately 4.9% of all 450 adverse event reports for this drug.
Patients taking MANGANESE SULFATE who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is moderately reported among MANGANESE SULFATE users, representing a notable but not dominant share of adverse events.
In addition to pulmonary embolism, the following adverse reactions have been reported for MANGANESE SULFATE:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 22 FDA reports for MANGANESE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 4.9% of all adverse event reports for MANGANESE SULFATE, making it a notable side effect.
If you experience pulmonary embolism while taking MANGANESE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.